1. Home
  2. ZNTL

ZNTL

Zentalis Pharmaceuticals Inc.

Logo Zentalis Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 3:03pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Founded: 2014 Country:
N/A
Employees: N/A City: NEW YORK
Market Cap: 919.6M IPO Year: 2020
Target Price: $43.57 AVG Volume (30 days): 826.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.47 EPS Growth: N/A
52 Week Low/High: $9.56 - $31.46 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -58.69%

Share on Social Networks:

Stock Insider Trading Activity of Zentalis Pharmaceuticals Inc. (ZNTL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Epperly Melissa B, ZNTL Chief Financial Officer Feb 12 '24 Sell $11.44 2,573 $29,435.12 451,449 SEC Form 4
Gallagher Cam ZNTL President Feb 12 '24 Sell $11.44 1,173 $13,419.12 643,277 SEC Form 4
Lackner Mark ZNTL Chief Scientific Officer Feb 1 '24 Sell $11.54 1,585 $18,290.90 195,728 SEC Form 4